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To patients, and their families, 





Mitochondrial diseases are inheritable diseases, where the function of the ATP 
(adenosine triphosphate) producing organelle of the cell, is compromised. This 
leads to a wide variety of phenotypes, known to arise from defects in over 200 
genes. Typically manifesting organs are brain, heart, muscle, liver, endocrine 
organs and sense organs. Mitochondrial disorders are often progressive, they 
can manifest in multiple organs in one person and due to inheritance, other 
family members might also be affected. Careful clinical assessment with 
investigation of family history helps to predict the cause, but other diagnostic 
assessments play a central role in diagnosis. 
Elevation of blood or cerebrospinal fluid lactate has traditionally been an 
indicator of mitochondrial dysfunction, but this biomarker lacks sensitivity and 
specificity, and more accurate biomarkers are required. Muscle biopsy sample 
is the gold standard of mitochondrial disease diagnosis. Cytochrome c oxidase 
(COX) negative, succinate dehydrogenase (SDH) positive fibers and ragged-
red fibers (RRFs) are hallmarks of mitochondrial dysfunction. Reduced 
respiratory chain enzyme activity in tissue verifies diagnosis. Solid diagnosis 
requires genetic evidence, but the expanding number of disease-causing 
genes makes it difficult to choose which genes to sequence. 
We report here a novel diagnostic serum biomarker, fibroblast growth factor 
21 (FGF21), which is more sensitive and specific to muscle-manifesting 
mitochondrial disorders than any of the conventional biomarkers used before. 
It correlates with COX-negative muscle fibers and is most likely produced and 
secreted by them. We also studied another recently discovered serum 
biomarker, growth differentiation factor 15 (GDF15). We report that both 
FGF21 and GDF15 correctly distinguish mitochondrial myopathies from non-
mitochondrial myopathies and controls, making them the most accurate 
biomarkers for mitochondrial myopathies to date. The trigger for induction of 
these biomarkers seems to be upstream of respiratory chain defect, most likely 
initiates from the mitochondrial translational machinery. 
In another study, we used next generation sequencing to search for a 
pathogenic mutation in a patient with fatal infantile Alpers 
hepatoencephalopathy. We identified two compound heterozygous mutations 
in a novel disease gene, FARS2. This gene encodes for a protein, 
mitochondrial phenylalanyl-tRNA synthetase (mtPheRS), responsible for the 
charging of mitochondrial phenylalanyl-tRNA with its cognate amino acid. 
Structural prediction of the mutated proteins together with functional studies in 
E. coli showing decreased activity of mutant mtPheRS, verified the diagnosis. 
Our results strongly support the use of FGF21 and GDF15 as first line 
diagnostic assessments. Rapid progression to next-generation sequencing is 
advised if both of these biomarkers are elevated, with positive predictive value 
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Mitochondria are the ATP-producing organelles of the cell. Dysfunction of 
mitochondrial ATP producing system, the respiratory chain (RC) and the ATP 
synthase, is the most common error of inborn metabolism (1). These disorders 
can manifest in nearly any organ of the body, in both children and adults. 
Typically, brain, muscle, liver, endocrine organs and/or sense organs are 
affected, sometimes with distinct combinations of symptoms. Severity ranges 
from fatal pediatric encephalopathies to mild restricted muscular dysfunction 
manifesting only in late adulthood. 
The RC and ATP synthase consist of more than 90 protein subunits 
encoded by both mitochondrial and nuclear DNA (nDNA). The first 
mitochondrial RC dysfunction causing mutations were found in the 
mitochondrial genome (mtDNA) in 1988, but since then, the number of known 
genetic defects in both genomes has grown tremendously (2). To date, more 
than 200 genes are known to cause a mitochondrial disorder. 
Diagnosis of these disorders is challenging due to the great variety of 
symptoms and their severity, tissue specificity of pathology, the many 
inheritance models possible and the varying penetrance of some diseases (3). 
Diagnosis begins with careful investigation of family history and clinical 
assessment of a patient followed by biochemical analyses of blood, urine 
and/or cerebrospinal fluid, tissue biopsy, imaging, electrophysiological 
examination and gene sequencing (4). Definitive diagnosis requires genetic 
diagnosis or an obvious defect in tissue mitochondrial RC function. 
This thesis summarizes the diagnostic assessments currently used and the 
advances our research has given to this field. We show how novel serum 
biomarkers (FGF21 and GDF15) perform in diagnosis and what the likely 
trigger for their induction is. We also show how next generation sequencing 
(NGS) can be a powerful tool when searching for mutations in novel disease 
causing genes for mitochondrial disorders. 
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2 REVIEW OF THE LITERATURE 
2.1 MITOCHONDRION AS AN ORGANELLE 
Mitochondria are intra-cellular organelles that have a distinct evolutionary 
origin. It is thought that an archaebacterium once engulfed an aerobic 
proteobacterium achieving greater capacity for aerobic respiration and thus a 
head start for cell survival (5). Over time, evolution has modified both the 
archaebacterium and the proteobacterium (now, mitochondrion) but some 
features still link the latter to a bacterium. First, human mtDNA is circular, 
instead of linear. The size of the genome used to be much larger, but most 
content has been incorporated to the host cell’s genome (6). Second, 
translation of mitochondrial proteins requires machinery that is similar to that 
of bacteria (7). This is of clinical relevance, while some antibiotics 
(aminoglycosides, tetracyclines) that are developed to prevent bacterial 
growth (more precisely, protein translation), also affect mitochondrial 
translation with considerable side effects (aminoglycoside-induced deafness) 
(8). Each mitochondrion is surrounded by a double membrane, of which the 
inner is highly invaginated, possibly to increase surface area for the 
mitochondrial respiratory chain (9). Inside the inner membrane is the 
mitochondrial matrix. 
2.1.1 MITOCHONDRIAL GENETICS AND PROTEIN SYNTHESIS 
 
Human mitochondrial DNA consists of 16,569 base pairs comprising 37 genes 
on two strands without introns. These genes contain the instructions for the 
making of 13 mitochondrial proteins, 22 transfer RNAs (tRNA) and two 
ribosomal RNAs (rRNA) (10), of which the RNAs are needed to produce the 
proteins (Figure 1). The 13 proteins are subunits of the respiratory chain 
complexes CI, CIII, CIV, as well as the ATP synthase (CV). A total of 93 
proteins are needed to build complexes I-V, the rest of them being encoded 
by the nuclear DNA. Complex II is the only RC complex consisting solely of 
nDNA encoded proteins. 
Every eukaryotic cell has numerous mitochondria (up to 100 000 in an 
ovum (11)), and every mitochondrion has several copies of mtDNA, with copy 
number typically being 2-10 per mitochondrion (10,11). MtDNA is covered with 
protein (mostly transcription factor A, TFAM) and packed into nucleoids that 
are attached to the inner mitochondrial membrane. TFAM is also known to 
regulate mtDNA copy number (14). 
The replication machinery needed for copying mtDNA in vitro is encoded 
by the nucleus and is very simple, consisting only of three proteins: the 
mitochondrial DNA polymerase gamma (POLG), single-stranded DNA-binding 
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protein (SSBP) and mitochondrial helicase TWINKLE (15). Unlike nuclear 
DNA, replication of mtDNA is independent of cell cycle (16, 17). 
 
 
Figure 1.  Mitochondrial DNA (mtDNA) and oxidative phosphorylation (OXPHOS). MtDNA 
encodes a minority of OXPHOS system (CI-CV) subunits, indicated as numbers of 
mtDNA encoded/nuclear encoded subunits above each complex. Colors in mtDNA 
indicate the complex the protein belongs to. Complex II is the only complex 
encoded fully by the nuclear DNA and it is also an enzyme of the TCA cycle. CI, CIII 
and CIV pump protons across the inner membrane to create an electrochemical 
force, which drives the synthesis of ATP by CV. NADH and FADH2 (products of 
TCA cycle) bring electrons (not shown) to CI and CII which transfer them to CoQ10-
> CIII->CytC. Cyt C carries these electrons to CIV and molecular oxygen (O2) to 
produce water (H2O). Single alphabets in mtDNA indicate tRNAs: A, alanine; C, 
cysteine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G, glycine; H, 
histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; Q, 
glutamine; P, proline; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; 
Y, tyrosine. HSP, transcription promoter of the heavy strand; LSP, transcription 
promoter of the light strand; OH, replication origin of the heavy strand; OL, 
replication origin of the light strand. H+, proton; CytC, cytochrome c; CoQ10, 
coenzyme Q10. HGNC approved gene symbols are used. Illustration: Kustaa 
Lehtonen 
 
There are several models of mitochondrial DNA replication, the strand 
displacement model being the first described (16, 18). In this model, replication 
is initiated at the heavy strand replication of origin (OH) after mitochondrial 
RNA polymerase (POLMRT) has synthetized a short RNA primer. The 
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replication machinery begins synthesis of complementary DNA from this 
primer, leaving the other strand (heavy strand) aside. It has been proposed 
that this strand is covered with SSBP probably to protect it from uncontrolled 
binding of the replicative enzymes or to mediate the contact between 
TWINKLE and POLG (19). Replication of the leading strand continues about 
two thirds of the full mtDNA circle, until it reaches the replication origin of the 
light strand (OL) (Figure 1). This OL is displaced from light (leading) strand and 
it forms a new stem-loop structure, which promotes initiation of the lagging 
strand DNA synthesis in the opposite direction. Both strands are then 
synthetized simultaneously until two copies of mtDNA are ready and 
separated from each other. Replication can proceed multiple rounds in a row. 
Often, at the beginning, leading strand replication is terminated soon after OH 
forming a triple stranded region of about 650bp, called the D-loop (18). 
Function of this loop is unknown, but hypotheses suggesting a role in mtDNA 
synthesis regulation and recruitment of replication machinery have been 
postulated (18) (Figure 1). 
Later, analysis of mtDNA from highly purified mitochondria with two-
dimensional agarose gel electrophoresis (2D-AGE) suggested another 
replication model, RNA incorporation during mtDNA replication (RITOLS). In 
the 2D-AGE, mtDNA replication intermediates form arcs based on their 
masses. Treating the mtDNA with restriction enzymes that only digest one or 
two stranded RNA or DNA revealed unexpected changes in 2D-AGE arcs, 
suggesting that some of the lagging strand is bound to complementary RNA 
instead of protein. In RITOLS, there are two replication origins instead of only 
one, both of which are in the D-loop area. (20)  
Synthesis of mitochondrially encoded proteins requires transcription of 
mtDNA by POLRMT together with TFAM and transcription factor B2 (TFB2M) 
or B1 (TFB1M, less active) (21). Transcription begins at the light strand 
promoter (LSP) and the heavy strand promoter (HSP) in the light and heavy 
strands respectively. Transcription is terminated by mitochondrial transcription 
termination factor MTERF1 (22) and the resulting messenger RNA (mRNA) is 
polycistronic, containing the instructions for multiple genes in one strand. 
Messenger RNA is processed by specific enzymes to cleave individual genes, 
tRNAs and rRNAs which are further modified for example by polyadenylation, 
or fold into correct secondary and tertiary structure (23). 
Next, in a process called translation, this mRNA functions as a scaffold for 
tRNAs in the presence of the mitochondrial ribosome (mitoribosome) and 
protein is formed from tRNA-bound amino acids. Amino acids are attached to 
the acceptor stem of cognate tRNAs by aminoacyl-tRNA synthetases (aaRSs). 
Translation is initiated by mitochondrial translation initiation factor 3 (IF3) that 
helps mRNA to bind to the small ribosomal subunit (SSU) (23). Translation 
initiation factor 2 (IF2) helps formylated tRNAMet (the first tRNA) to bind SSU 
and the start codon in mRNA. The large ribosomal subunit (LSU) is attached 
to the complex while IF2 and IF3 are released. In translation elongation, mRNA 
moves through mitoribosome while it is read three nucleotides (a codon) at a 
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time. Translation elongation factor Tu (TUFM) binds to aminoacylated tRNA 
(the second tRNA) and after proofreading, carries it to the mitoribosome, 
where tRNA is recognized by the anticodon site and TUFM is released. 
Adjacent tRNA-bound amino acids are linked to each other and nascent 
polypeptide exits the mitoribosome. Translation elongation factor G (GFM1) 
catalyzes the translocation of these tRNAs to the next positions in the 
mitoribosome while it moves one codon forward. A third tRNA enters while the 
first tRNA exits the mitoribosome (Figure 2). This elongation process is 
repeated until one of the stop codons of mRNA is reached. Stop codons are 
recognized by translational release factor RF1 (MTRF1), which causes the 
ready polypeptide chain to be released from the tRNA for further modifications. 
Translation factors and ribosomal subunits are recycled for another round of 
translation. The whole process requires energy in the form of guanosine 
triphosphate, GTP (23). 
 
 
Figure 2.  Simplified illustration of mitochondrial translation. Aminoacyl-tRNA synthetase 
(blue) catalyzes the attachment of amino acid (green) to its cognate tRNA. While 
mitochondrial ribosome (orange) moves along mRNA, tRNAs bind to it according to 
codon sequence. tRNA- bound amino acids are attached to each other by covalent 
bond, forming polypeptide chain that exits the ribosome. The polypeptide chain is 
further modified to produce a fully functioning protein. LSU, large subunit; SSU, 
small subunit; tRNA, transfer RNA; mRNA, messenger RNA; aa, amino acid; aaRS, 
aminoacyl-tRNA synthetase. Illustration: Kustaa Lehtonen 
2.1.2 ATP PRODUCTION BY OXIDATIVE PHOSPHORYLATION 
Mitochondria are the sites where dietary energy is converted to ATP in the 
process of oxidative phosphorylation (OXPHOS). This procedure requires 
oxygen and is highly efficient: it produces 32 units of energy per glucose 
molecule while anaerobic glycolysis produces only two. 
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First, dietary carbohydrates, protein and triglycerides are metabolized by 
specific enzymes to produce acetyl-coenzyme A (acetyl-CoA). This metabolite 
then enters the mitochondrial citric acid cycle (TCA cycle, Kreb’s cycle) (24), 
where it is further metabolized in multiple steps. These reactions produce 
(among others) reducing equivalents NADH (nicotinamide adenine 
dinucleotide) and FADH2 (flavin adenine dinucleotide), which are needed as 
electron donors in the electron transport chain located in the inner 
mitochondrial membrane. 
The electron transport chain consists of four complexes. Complex I (NADH 
dehydrogenase) oxidizes NADH and shuttles electrons to coenzyme Q10 
(CoQ10, ubiquinone). Complex II is also a TCA cycle enzyme, succinate 
dehydrogenase, which converts succinate to fumarate yielding FADH2. Similar 
to NADH, FADH2 donates electrons to CoQ10. Oxidized NADH (NAD+) and 
FADH2 (FAD) are recycled back to TCA cycle. CoQ10 moves along the inner 
membrane, carrying the electrons from CI and CII to complex III (CoQ10-
cytochrome c oxidoreductase). This complex subsequently moves the 
electrons from oxidized CoQ10 (ubiquinol) to cytochrome c, a water-soluble 
electron carrier of the intermembrane space. Finally, the electrons are donated 
to molecular oxygen (O2) in complex CIV (cytochrome c oxidase), producing 
water (H2O). Complexes I, III and IV also pump protons (H+) across the inner 
mitochondrial membrane creating an electrochemical gradient, which is 
utilized by complex V (ATP synthase) in a reaction where ADP (adenosine 
diphosphate) is phosphorylated to ATP (Figure 1). (25, 26)  
Besides nuclear and mitochondrial-encoded subunits of RC, proper 
function of the complexes requires additional nuclear encoded assembly 
factors (Table 1). Complexes form dimers and polymers and even larger 
supercomplexes, where different complexes are associated with each other in 
a functional unit. Complex II is the only complex not found in these 
supercomplexes. ATP synthase is a dimer, often found on the curvatures of 
the inner mitochondrial membrane, whereas the other complexes are located 
on the flat area. Tight connection of complexes is thought to prevent formation 
of free radicals as leakage of electrons from the RC is minimized when 
electrons are shuttled from one complex to another in close proximity. 
Complexes are shown to be more stable in supercomplexes than alone yet a 
mutation in one complex subunit might also affect the stability of another 
complex. (26)  
Occasional electron leakage from the RC happens, creating reactive 
oxygen species (ROS). These free radicals are important signaling molecules, 
but toxic in large quantities. Uncontrollable production of ROS causes 
mutagenesis and cellular damage resulting in mitochondrial dysfunction, 
tumor formation, ageing, apoptosis and necrosis. (27)  
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2.1.3 OTHER FUNCTIONS OF MITOCHONDRIA 
Despite cells’ high requirement for ATP, OXPHOS is not the only important 
function of mitochondria. Under some conditions, cells survive without 
mitochondrially produced ATP, but never does a eukaryotic cell remain viable 
without iron-sulphur (Fe-S) cluster dependent protein (28). These clusters are 
synthesized in mitochondria and some are exported to the cytosol. Fe-S 
containing proteins are essential for nuclear genome maintenance, gene 
expression and stability (28). 
Folate (vitamin B9) cycle partially localizes to mitochondria, using serine, 
glycine and sarcosine to produce, among others, formyl-methionine needed 
for mitochondrial translation initiation (29). Fatty acids enter mitochondria by 
carnitine shuttle as acyl-CoA esters, which are metabolized in the 
mitochondrial matrix by beta-oxidation to acetyl-CoA, which enters the TCA 
cycle. 
In addition, mitochondria participate in various cellular processes such as 
heme and biotin (vitamin B7) synthesis, calcium storage and programmed cell 
death (30). 
2.2 MITOCHONDRIAL DISORDERS 
Mitochondrial diseases are the most common inborn errors of metabolism with 
a very heterogeneous genetic aetiology resulting in a wide spectrum of 
phenotypes (Table 1). Currently 1200-1300 genes are known to encode a 
mitochondria-linked protein (most of them listed in MitoCarta 2.0 (31, 32)), 
while only 250-300 of them are known to cause disease (The Mitochondrial 
Disease Sequence Data Resource Consortium (MSeqDR, 
https://mseqdr.org/)). Only a proportion of these, however, primarily affect the 
mitochondrial RC, causing primary OXPHOS disorders, the focus of this thesis 
(Table 2). The prevalence of primary OXPHOS disorders is estimated as 
1/2000- 1/10 000 live births (33–37). 
Mortality in pediatric mitochondrial disorders is 10-50% per year after 
diagnosis and 5-20% per year after clinical onset of symptoms in adulthood 
(35). However, prognosis depends greatly on the genotype and phenotype: 
severe early-onset encephalopathies (Leigh, Alpers) naturally have a poor 
prognosis (38, 39) as compared to isolated muscle weakness of the external 
ophthalmic muscles (progressive external ophthalmoplegia, PEO). Early 
diagnosis and treatment of both the primary disease and its complications is 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.2.1 GENETICS OF PRIMARY OXPHOS DISORDERS 
Primary OXPHOS disease genes encode for proteins that are closely linked 
to OXPHOS complexes. Proteins affecting mtDNA replication and 
maintenance or synthesis of deoxynucleotide triphosphates (dNTPs) cause 
point mutations or deletions in mtDNA and/or a reduction in mtDNA quantity 
(depletion). Translation of mtDNA-encoded proteins is impaired when the 
defect affects rRNA, tRNA, tRNA modification, aminoacylation of tRNAs, 
mRNA processing, ribosomal function or translation factors. Defects in RC 
subunits or their assembly factors have a direct impact on respiratory chain 
structure and function. Single large-scale mtDNA deletions (ΔmtDNA) cause 
OXPHOS deficiency by affecting multiple mtDNA-encoded proteins/RNA at 
the same time. It is estimated that 75% of adult mitochondrial disorders are 
caused by mutated mtDNA, whereas in children the proportion is more 
modest, 10-25% (40). 
Some of the disease-causing mutations arise de novo, meaning the 
mutation took place during or right after fertilization of this individual. This 
mutation is not likely to occur again in the siblings and it is not present in the 
parents. These mutations are dominant and have been hard to find due to 
large quantity of heterozygous variants in the genome. Recent development 
in sequencing technologies has enabled the finding of these as well (41), 
although not yet in primary OXPHOS disorders (42). More frequent is that the 
mutation is passed on from one generation to the next in autosomal recessive, 
autosomal dominant, X-linked or maternal manner. In this case, the likelihood 
of a person to manifest with a disease depends on the inheritance model, 
penetrance and in the case of mtDNA mutations, the heteroplasmy of the 
mutant DNA (see below). 
Variant frequency in different populations is affected by population 
genetics, with the founder effect and the bottleneck phenomenon having an 
important role. GRACILE syndrome (growth retardation, aminoaciduria, 
cholestasis, iron overload, lactic acidosis, and early death) is a disorder 
belonging to the Finnish disease heritage with one founder mutation (43). It is 
caused by a mutation in BCS1L, encoding for a protein involved in CIII 
assembly. Similarly, in patients with myopathic mitochondrial depletion 
syndrome caused by either of the two homozygous TK2 mutations, a Finnish 
and possibly a Scandinavian founder were implicated (44). 
2.2.1.1 Mitochondrial DNA: maternal inheritance 
 
All eukaryotic cells, except mature erythrocytes, have mitochondria. After 
fertilization of an egg, the sperm cell mitochondria, however, are actively 
degraded in the zygote. Because of this, the mitochondrial genome is solely 
maternally inherited making it impossible for fathers to pass on pathogenic 
mtDNA to their offspring (with rare exception (45)). 
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Mitochondrial DNA defects can vary from single nucleotide variations 
(SNVs) to larger scale deletions, the most common ΔmtDNA being 4.9kb in 
size. Large deletions of mtDNA are not transmitted to offspring (with few rare 
exceptions (46, 47)). As healthy (wild type) mtDNA is typically homoplasmic, 
mutations in mtDNA are usually heteroplasmic, meaning there is also normal 
mtDNA in the cells. The level of mutated mtDNA, called the heteroplasmy, 
affects the clinical presentation of the disease, with high variation. Mutations 
in mitochondrial CV subunit gene MTATP6 (mitochondrial ATP synthase 
subunit 6) cause neurogenic muscle weakness, ataxia and retinitis 
pigmentosa (NARP) or maternally inherited Leigh syndrome (MILS) depending 
on the heteroplasmy level. Having <40% of this mutated mtDNA typically does 
not cause a disease, but >90% causes early onset fatal encephalopathy 
(MILS). In contrast, a fairly common mtDNA point mutation, m.3243A>G, 
causes a wide spectrum of clinical manifestations ranging from maternally 
inherited diabetes and deafness (MIDD) to mitochondrial encephalomyopathy, 
lactic acidosis and stroke-like episodes (MELAS), but the presentation is not 
attributed to the heteroplasmy level (48). Some mutations may occur as 
homoplasmic, as in Leber’s hereditary optic neuropathy (LHON) (49), but not 
all LHON mutation carriers manifest the disease (due to varying penetrance, 
male predominance). Environmental factors (smoking, alcohol usage, low fruit 
consumption) are associated with disease expression, but the causal 
relationship of these two is unknown (49). Association of mtDNA haplogroup 
with disease manifestation has also been reported (50). 
Depletion of mtDNA is a consequence of mutations affecting mtDNA 
replication and maintenance. Genes that are responsible for mtDNA 
replication and maintenance (POLG, TWNK, TK2, RRM2B, TYMP, DGUOK) 
cause depletion in addition to mtDNA mutagenesis (51). Depletion causes 
incapability to express and synthesize sufficient amount of mtDNA encoded 
products, resulting in an OXPHOS defect (51) (Table 1). 
Despite maternal inheritance, a mother with an mtDNA disease can still 
have healthy babies spontaneously (see also treatment section chapter 
2.2.4.3). After egg fertilization, mitochondria are distributed to daughter cells 
without mtDNA replication, resulting in a decrease in mtDNA copy number per 
cell. Segregation of mtDNA is thought to happen in a controlled fashion, all 
daughters (stem cells of developing tissues) being equal in heteroplasmy (52). 
After numerous cell divisions, primordial germ cells however, have such a 
small number of mtDNA copies (possibly even only 10 copies (52)) that a small 
variation in the absolute mutant mtDNA copy number is proportionally large 
(Figure 3). This is called the bottleneck of mtDNA segregation. During further 
development of female primordial germ cells (oogenesis), copy number will 
increase again at least 2000 fold (52) resulting in a wide range in mtDNA 
heteroplasmy of mature eggs. Thus, a mother with a low heteroplasmy and no 




Table 2.  Listed are genes (and ΔmtDNA) known to cause a primary OXPHOS deficiency. 
Genes are categorized to four groups, first three of them being the same as in 
paper II. Asterisk indicates genes that also cause mtDNA depletion. Genes are 
taken from mSeqDR database (https://mseqdr.org/), Gorman GS et al 2016 and 






tRNA 22 mtDNA encoded tRNAs
aminoacyl tRNA 
synthetases
AARS2, CARS2, DARS2, EARS2, FARS2, HARS2, IARS2, 
LARS2, MARS2, NARS2, PARS2, RARS2, SARS2, 
TARS2, YARS2, VARS2, KARS, GARS, WARS2
tRNA modification  ELAC2, GTPBP3, HSD17B10, MTFMT, MTO1, TRIT1, 
TRMT5, TRMU, PUS1 
mRNA modification LRPPRC, MTPAP, PNPT1
ribosomal function MRPL3, MRPL12, MRPL44, MRPS7, MRPS16, MRPS22
translation factors AFG3L2, C12orf65, GFM1, GFM2, RMND1, SPG7, TACO1, 
TUFM, TSFM
nucleoside pools DGUOK*, TK2*, TYMP*
mtDNA replication DNA2, POLG*, POLG2, TWNK*
mtDNA 




MTND1, MTND2, MTND3, MTND4, MTND4L, MTND5, 
MTND6, NDUFA1, NDUFA2, NDUFA9, NDUFA10, 
NDUFA11, NDUFA12, NDUFA13, NDUFAF6, NDUFB3, 
NDUFB9, NDUFB11, NDUFS1, NDUFS2, NDUFS3, 
NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFV1, 
NDUFV2
CI assembly FOXRED1, NDUFAF1, NDUFAF2, NDUFAF3, NDUFAF4, 
NDUFAF5, NUBPL
CII subunits SDHA, SDHB, SDHD
CII assembly SDHAF1, SDHAF2
CIII subunits LYRM7, MTCYB, TTC19, UQCC2, UQCC3,  UQCRB, 
UQCRC2, UQCRQ 
CIII assembly BCS1L, HCCS
CIV subunits MTCO1, MTCO2, MTCO3, COX412, COX6B1
CIV assembly COA5, COX10, COX14, COX15, COX20, PET100, SCO1, 
SCO2, SURF1
CV subunits ATP5A1, ATP5E, MTATP6, MTATP8
CV assembly ATPAF2, TMEM70
CoQ10 synthesis COQ2, COQ4, COQ6, COQ8A, COQ8B, COQ9, PDSS1, 
PDSS2











Abbreviations: rRNA, ribosomal RNA; tRNA, transfer RNA; CI-CV,OXPHOS complexes I to V; CoQ10, 
coenzyme Q10; TCA cycle, tricarboxylic acid cycle; ΔmtDNA, single large scale deletion of mtDNA. HGNC 
approved gene symbols are used, where prexif "MT" refers to mtDNA origin.
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There seems to be purifying selection against pathogenic mutations in 
mtDNA as nonsynonymous changes appear to be less frequent in  protein-
coding regions than synonymous (53). Still, in the case of MTATP6 mutation 
m.T8993G, segregation seems to favor the mutated form (54–59). Random 
segregation of mtDNA happens after organ development, when cells within 
tissues have different levels of heteroplasmy. This is seen in muscle histology 
of mitochondrial disease patients, where COX-negative fibers are shown to 
have a higher heteroplasmy than the COX-positive fibers next to them (60). 
 
Figure 3.  Uneven segregation of mtDNA from zygote to primordial germ cells due to the 
bottleneck phenomenon. Purifying selection further modifies the heteroplasmy of 
daughter cells. Illustration: Kustaa Lehtonen 
 
2.2.1.2 Nuclear DNA: recessive, dominant and X-linked inheritance 
 
Nuclear genes are inherited from father and mother, one copy of each 
chromosome from each parent, except the sex chromosomes. In some 
diseases it is sufficient to have one copy of a defective gene (dominant 
inheritance), whereas in some, two defective copies are needed (recessive 
inheritance). In the former, one of the parents has the same disease as child 
(unless mutation has occurred de novo), whereas in the latter, both parents 
are heterozygous carriers of the mutation without clinical manifestation. The 
two alleles of the gene can have the same (homozygous) or different 
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(compound heterozygous) mutation. Examples of recessive diseases include 
Alpers, mitochondrial recessive ataxia syndrome (MIRAS) and autosomal 
recessive PEO (arPEO). An example of autosomal dominant disease is 
autosomal dominant PEO (adPEO) (Table 1). 
X-linked disorders are typically recessive and thus only manifest in men. 
These disorders are inherited from mother (a carrier) to son, while daughters 
have a 50% chance to become carriers. Manifesting fathers pass on this 
chromosome to their daughters, who become carriers, but sons only inherit Y-
chromosome from father. An example of an X-linked mitochondrial disorder 
(not a primary OXPHOS disorder) is Barth syndrome, affecting tafazzin gene 
(TAZ) causing cardiomyopathy, myopathy, neutropenia, 3-methylglutaconic 
aciduria and poor growth (61). 
2.2.2 PHENOTYPE 
Mitochondrial diseases cause a wide spectrum of manifestations with a great 
variation in clinical presentation even with the same underlying mutation (62). 
Multi-tissue presentation of symptoms, varying phenotype within a family and 
progressive nature of disease are typical for mitochondrial disorders (63). 
Mitochondrial disorders can manifest in newborns or later in life. In a cohort 
of 100 pediatric mitochondrial disease patients, 80% of them manifested 
before the age of two (64). Presumably a portion of fetal deaths is explained 
by severe mitochondrial dysfunction, since despite the existence of 
heterozygous carriers, some mutations are never found as homozygotes (65, 
66).  
It is typical that an environmental factor, such as illness, infection, surgery, 
prolonged fasting or medication elicits deterioration of symptoms in 
mitochondrial disease (67). Examples of medication-induced mitochondrial 
dysfunctions are valproate induced liver failure (typical in patients with POLG 
mutations (68)) and aminoglycoside induced hearing loss (8). 
Mitochondrial diseases can be very tissue specific (muscle tissue in TK2 
mutations (69) and brain in DARS2 mutations (65, 70)) and even cell-type 
specific (retinal ganglion cells in LHON (71), pancreatic beta cells in MIDD), 
but also multi-organ manifestation in distinct combinations are common. Listed 
in Table 1 are the most common primary OXPHOS disorders, their genetic 
background and typical symptoms. 
One of the severe childhood-onset mitochondrial disorders is Alpers 
syndrome (or Alpers-Huttenlocher syndrome, used in case of additional liver 
manifestation). The disorder was originally described by Bernard Alpers, who 
discovered the typical neuropathological findings in the cerebral, and 
sometimes cerebellar cortices, and thalamus: necrosis (microcystic 
degeneration, capillary proliferation), neuronal loss (gliosis) and spongiosis 
(39, 72). Involvement of calcarine and striate cortices presents as blindness. 
It is a disorder causing (hepato) cerebral mtDNA depletion, due to recessive 
(homozygous or compound heterozygous) POLG (71, 37), TWNK (74) or  
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MTCO2 (cytochrome c oxidase subunit II) mutations (75). Age of onset is 
typically between two and four years of age. The diagnostic triad of this 
disorder is developmental delay, intractable seizures, and liver failure (Alpers-
Huttenlocher syndrome). Additional diagnostic symptoms include cortical 
blindness and optic atrophy. Valproic acid is liver-toxic for Alpers patients (76). 
Abnormal diagnostic findings are reduced N-acetyl L-aspartate (NAA) in 
magnetic resonance spectroscopy (MRS), elevated blood and cerebrospinal 
fluid (CSF) lactate and CSF protein, abnormal activity in 
electroencephalogram (EEG), decreased POLG activity and isolated defect in 
CIV or combined defect in CI, CIII and CIV activities. Neuropathological 
findings include neuronal loss, spongiform degeneration and astrocytosis of 
the cortex. Liver shows steatosis and cirrhosis. This disorder is progressive, 
leading to fatal encephalopathy or liver failure and often death within four years 
after first symptoms.(39)  
2.2.3 DIAGNOSIS OF MITOCHONDRIAL DISORDERS 
Careful clinical assessment includes anamnestic interview with investigation 
of family history. Family members might have a very different phenotype (77–
79), and thus active family tracing and examination of family members is 
informative. 
There are multiple disease scoring systems, for both adults and children, 
which help to determine whether a disease is of mitochondrial aetiology (80–
82). Symptoms and findings are scored and total score reflects the likelihood 
or a mitochondrial disorder ranging from unlikely to definite. A typical 
diagnostic pathway is represented in Figure 4. 
2.2.3.1 Biochemical analyses 
Elevated lactate is a typical hallmark of mitochondrial disorders. Lactate is 
produced from pyruvate, which is normally oxidized to acetyl-coA, which 
enters the TCA cycle. However, when OXPHOS is impaired, pyruvate is 
reduced to lactate to produce ATP. This increases the lactate to pyruvate ratio 
(L/P), a surrogate measure of cytoplasmic NADH/NAD+ ratio. A study by 
Debray FG et al showed that when lactate is >5mmol/l, high L/P (>25.8) 
correctly distinguishes mitochondrial diseases (in this study, MELAS, KSS 
(Kearns-Sayre syndrome) and mitochondrial myopathy with ragged red fibers) 
from pyruvate dehydrogenase deficiency (PDHD) (83). Lactate and pyruvate 
can also be measured in CSF. Compared to blood, CSF lactate is less prone 
to false positivity, but such lack of specificity exists due to central nervous 
system tumor, inflammation, infection, stroke or seizure (84) and thus should 
be measured in a chronic steady state of disease. Repeated lactate 
measurements are used in treadmill or bicycle ergometry to reveal inadequate 
oxygen utilization or impaired lactate removal. 
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Creatine (phospho) kinase (CK) is an enzyme abundant in muscle tissue, 
and it catalyzes the conversion of creatine to phosphocreatine, another high-
energy phosphate molecule besides ATP. Serum CK is used in the diagnosis 
of muscular dystrophies (85) and thus helps in differential diagnosis. 
Elevated plasma alanine is occasionally detected in long-standing pyruvate 
overload, and it is indicative for a mitochondrial disease (4). Elevated plasma 
or urine amino acids, organic acids, (acyl) carnitine, CoQ10, ammonia and 
TCA cycle intermediates are also used in (differential) diagnosis, all 




Figure 4.  Typical diagnostic pathway for mitochondrial disorders. Abbreviations: L, lactate; P, 
pyruvate; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; MRS, 
magnetic resonancy spectoscopy; NAA, N-acetyl L—aspartate; EMG, 
electropmyography; EEG, electroencephalography; ECG, electrocardiogram; 
OXPHOS, oxidative phosphorylation; mtDNA, mitochondrial DNA. Figure modified 
from Gorman et al 2016 and Haas et al 2008. 
2.2.3.2 Magnetic resonance imaging (MRI) 
MRI findings are typically not diagnostic alone and a normal finding does not 
rule out a mitochondrial disorder (4). Leigh disease is a neuroradiological 
diagnosis with bilateral symmetrical changes in brain stem and basal ganglia, 
and especially in putamina. MELAS is suspected when stroke-like lesions, not 
following vascular territories are detected (87). Leukoencephalopathy with 
brain stem and spinal cord involvement and high brain lactate (LBSL) caused 
by defective DARS2 gene (mitochondrial aspartyl-tRNA synthetase) is an 
exception to this, as the brain MRI pattern is very specific (65, 88, 89). 
In Alpers syndrome, occipital regions might show changes reflecting 
neuronal loss and gliosis. Hyperintensities are prominent in thalami and basal 
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ganglia when seizures are uncontrolled. Later, atrophy of basal ganglia and 
brain stem is visible with occasional cerebellar involvement. (39)  
Magnetic resonance spectroscopy (MRS) uses the same signals as MRI to 
calculate the concentration of substances in the brain. In mitochondrial 
disorders, MRS might show high lactate peak in the central nervous system 
(CNS) (4). NAA is produced in mitochondria from aspartic acid and acetyl-CoA 
(90), and its quantity is used as a proxy of neuronal integrity (4). Large 
succinate peak may also be seen in patients with succinate dehydrogenase 
(CII) defects (91). 
2.2.3.3 Tissue biopsy samples 
Muscle tissue biopsies (or sometimes liver or heart biopsy samples) play an 
important role in the diagnosis of mitochondrial disorders, since they offer 
material for a wide variety of analyses. MtDNA heteroplasmy is preferably 
determined from post-mitotic tissue sample, since in some cases, 
heteroplasmy tends to fall in peripheral blood with age (92–94). Besides 
muscle, cells of urine sample or buccal mucosa swipe sample give a reliable 
heteroplasmy result. Biopsy samples offer material for a wide spectrum of 





Figure 5.  Immunohistochemical activity staining of muscle tissue from a patient with 
progressive external ophthalmoplegia (PEO). Cytochrome c oxidase (COX, in 
brown) weak or negative fibers colocalize with succinate dehydrogenase (SDH, in 







The most prominent histological hallmark for mitochondrial diseases in muscle 
are ragged-red fibers (RRFs), a sign of mitochondrial proliferation (95). The 
red appearance in Gomori trichrome staining is due to accumulation of 
abnormal mitochondria near plasma membrane of the cell. They are most 
common in disorders arising from dysfunctional mitochondrial translation or 
mtDNA deletions. Among children, RRFs are less common, and associate with 
specific gene defects, including TK2-gene defect (4, 96). 
Histochemical activity analysis of RC complex IV (cytochrome c oxidase, 
COX) is routinely done simultaneously with complex II (succinate 
dehydrogenase, SDH) activity measurement. COX weak or negative fibers are 
indicative for a mitochondrial disorder, especially when the same fibers are 
abundant in SDH (Figure 5). SDH intensity reflects mitochondrial proliferation, 
which is induced as RC function diminishes. Complex II induction is possible 
even in mitochondrial translation defects, since CII is solely encoded by the 
nucleus. 
Immunohistochemical stainings can be suggestive for genetic diagnosis, 
particularly when only one of the complexes is disrupted. This can indicate 
lack of assembly (defective SURF1 in CIV defect) (97) or lack of a complex 
subunit. 
 
2.2.3.3.2 RC enzyme activity analysis by spectrophotometry 
 
Detection of a biochemical OXPHOS defect in a tissue mitochondrial 
preparation is done by giving it enzyme-specific substrates and measuring the 
enzyme activity relative to citrate synthase activity (4). A combined defect in 
complex activities might indicate a mitochondrial translational defect (CII not 
affected). Measuring coupled enzyme activities (I+III and II+III) may reveal 
defects in CoQ10 pathway, which can be verified by detecting decreased 
CoQ10 levels in tissue (4). Another assay, polarography, measures the 
amount of oxygen consumed by mitochondria when different substrates are 
given. This is less frequently available, because it requires a fresh tissue 
sample, but adds diagnostic sensitivity to standard RC analysis (98). Also, 
ATP synthesis capacity can be measured from isolated mitochondria. 
 
2.2.3.3.3 Importance of tissue biopsy sample for research 
 
Cells are excellent material, when pathogenicity of novel disease genes is 
being validated. Detection of a dysfunction in cells, and rescuing the 
phenotype with a wild type gene is good evidence for variant pathogenicity. 
Cells obtained from tissue samples can be cultured as such, or they can be 
stimulated to become induced pluripotent stem (iPS) cells. These cells have 
the potential to become any cell type of the organism. Regarding the high 
tissue-specificity of mitochondrial disorders, this approach might help to gain 
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access to cells from a tissue not eligible for tissue biopsy (i.e. brain). Cultured 
cells are also virtually an endless source of DNA. In addition, fibroblasts can 
be frozen and thawed for culture as novel diagnostic methods appear. 
2.2.3.4 Genetic diagnostic testing 
Finding a genetic diagnosis is the most exact way to achieve a definite 
mitochondrial disease diagnosis. Disease phenotype, model of inheritance 
and results of other assessments determine the best suitable genetic 
diagnostic test. 
 
2.2.3.4.1 mtDNA sequencing 
 
When inheritance pattern or disease phenotype strongly suggest a defect in 
the mitochondrial genome, mtDNA can be fully sequenced. The phenotype of 
the most common mtDNA point mutation, m.3243A>G, varies greatly 
hindering quick diagnosis (99). Still, single nucleotide analysis is appropriate 
when for example MIDD is suspected (Table 1). 
 
2.2.3.4.2 mtDNA quantity 
 
Real time quantitative PCR (qPCR) analysis reveals low mtDNA quantity 
(depletion). Such depletion in muscle is typically seen in diseases caused by 
mutations in TK2, RRM2B, SUCLA2 and SUCLG1 (86), the last three showing 
also central nervous system manifestation. A hepatocerebral form of mtDNA 
depletion syndrome is caused by defects in genes MPV17, POLG, TWNK, 
DGUOK and TFAM (86, 100). Such small panels of known causative genes 
enable targeted sequencing of the candidate nuclear genes. 
 
2.2.3.4.3 Sequencing of nuclear candidate genes 
 
Sequencing of candidate genes is possible if the phenotype is specific to a 
certain genotype. As mentioned earlier, this is the case in patients with LBSL 
caused by mutations in DARS2, where brain MRI is already diagnostic. 
Another example is patients with TK2 mutation, where mtDNA depletion 
together with a severe dystrophy is highly suggestive for mitochondrial 
myopathy, even to the degree of a specific nucleotide change in the Finnish 
population (44). Genetic studies are then used only to verify diagnosis. In most 
cases, however, candidate disease genes are so many, that sequencing 
individual genes becomes too laborious and expensive (101). Currently, a 
mitochondrial gene panel can be even cheaper than sequencing of a one large 





2.2.3.4.4 Next generation sequencing (NGS) 
 
Next generation sequencing is a massively parallel, high throughput 
sequencing technology developed during the past decade. It is highly efficient 
as hundreds or thousands of genes are sequenced simultaneously. Together 
with mtDNA, one can sequence for example 1) all nuclear genes known to 
cause a specific mitochondrial disorder (a custom-made panel) 2) all genes 
encoding a mitochondria-localized protein (MitoCarta 1.0, 1034 genes, (102)) 
3) all coding regions of nuclear DNA (the Exome) 4) full genomic DNA 
including introns and non-coding regions (the Genome) (42). 
NGS enables detection of a pathogenic variant in a single patient (103, 
104), detection of novel disease genes (29, 105, 106) and detection of novel 
phenotypes in a known disease gene (107, 108). 
2.2.3.5 Differential diagnosis 
Differential diagnosis for mitochondrial diseases are multiple, demanding 
clinical pattern recognition. 
Mitochondrial axonal neuropathy can resemble Charcot-Marie-Tooth 
disease, a neuropathy known to be caused by multiple gene defects. A 
mitochondrial neuropathy can also resemble inflammatory or autoimmune 
disorder. (109)  
Central nervous system manifestations include epilepsy, encephalopathy, 
stroke-like episodes and ataxia. Epilepsy could be caused by an encephalitis 
or epilepsy syndrome and myoclonic epilepsy by ceroid lipofuscinosis or 
gluten encephalopathy. Mitochondrial epilepsy is typically accompanied with 
encephalopathy or other clinical features. Mitochondrial stroke-like episodes 
are distinguishable from ischemic stroke by the presence of a prodrome 
(migraine, flashing light, visual disturbance) and by the brain MRI: lesions 
caused by stoke-like episodes do not follow vascular territories and tend to 
change over time. Cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy (CADASIL) causes strokes, dementia and 
migraine, but is caused by a NOTCH3 gene defect. Increased protein 
concentration in CSF is typical in CNS vasculitis. Purely cerebellar ataxia is 
rare in mitochondrial disorders and could be caused by toxic (alcohol), 
metabolic, inflammatory and degenerative causes. Fragile X associated 
tremor/ataxia syndrome (FXTAS) and vitamin E deficiency are non-
mitochondrial causes of ataxia, whereas Friedreich’s ataxia is a secondary 
mitochondrial ataxia.(109)  
Mitochondrial PEO could be mixed with myasthenia gravis or 
oculopharyngeal muscular dystrophy, but in contrast to these, the severity of 
muscle weakness in mitochondrial PEO does not fluctuate and does not affect 
other facial musculature. Nemaline myopathy, myotonic dystrophy type 1 and 
desminopathy could also present as ptosis in addition to generalized muscle 
weakness. Limb-girdle syndromes and Dok-7 congenital myasthenic 
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syndromes typically cause induction of serum creatine kinase, which is rare in 
mitochondrial disorders (109). 
An OXPHOS defect detected in muscle tissue might also be secondary. 
Spinal muscular atrophy (SMA), limb-girdle muscular dystrophy (LGMD), 
inflammatory myopathies and amyotrophic lateral sclerosis (ALS) are 
diseases where secondary mitochondrial defects are seen (110). Aging is 
associated with accumulation of point mutations and deletions in mtDNA and 
presence of COX-negative muscle fibers (111). Mitochondrial dysfunction 
might be present in for example copper-metabolism disorders, lysosomal 
disorders and peroxisomal disorders. Elevated blood lactate is a hallmark of 
mitochondrial disorders but present also in other inborn errors of metabolism. 
Visual impairment could be caused by inflammation or structural 
pathologies as well as other genetic causes. Wolfram’s and Usher’s 
syndromes cause visual loss together with hearing deficiency. Susac’s 
syndrome causes occlusion of microvessels in the brain, retina and inner ear 
via an autoimmune pathology. (109)  
Mitochondrial parkinsonism presents typically with additional symptoms. 
The neurodegenerative features of Huntington’s disease can falsely be 
interpreted as mitochondrial features although chorea is rare in mitochondrial 
disorders and typical in Huntington’s disease. (109)  
A multisystem disorder might suggest congenital glycosylation disorders or 
Marinesco-Sjögren syndrome. (67)  
2.2.4 TREATMENT OPTIONS 
 
Despite the first genetically verified mitochondrial disorder being described 
almost 30 years ago (112), there is currently no cure for these disorders (with 
the exception of CoQ10 deficiencies). However, a growing understanding of 
the mechanism of many mitochondrial disorders, has led to the discovery of 
therapies that improve survival and life quality. 
Besides specific treatments, all patients should receive appropriate 
symptomatic and supportive management. Symptomatic medicine (avoidance 
of mitochondria-toxic drugs), individually designed exercise, medical 
equipment (cochlear implant, cardiac pacemaker), sufficient and personalized 
diet (avoid fasting), vaccination against infections and peer support are key 
factors in improving life quality of patients. (113)  
2.2.4.1 Supplements 
Many “mitochondrial cocktails” are used to treat a wide variety of mitochondrial 
disorders. Typically, they contain a variety of vitamins and supplements in high 
doses. There are few double blind, placebo-controlled studies evaluating their 
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efficacy and since these drugs also have possible harmful side effects, their 
wide usage cannot (yet) be recommended. (113, 114)  
Coenzyme Q10 deficiency is treated with ubiquinol supplementation, a 
better absorbed, reduced form of CoQ10 (ubiquinone) (113). Intravenous 
administration of L-arginine might enhance outcome in patients with stroke-
like episode due to MELAS (115). 
It is worth noting that some mitochondria-affecting disorders that are not 
primary OXPHOS disorders, are treatable. Mitochondrial coenzyme 
deficiencies could be treated by supplementation of the coenzyme, such as 
thiamine and biotin in biotin-thiamine-responsive basal ganglia disease and 
biotin in biotinidase deficiency. (116)  
2.2.4.2 Organ transplantation 
Solid organ (heart, kidney, liver) transplantation in mitochondrial disorders was 
studied by Parikh et al in a retrospective study (113). After transplantation, 
they detected no acute deterioration of the underlying disease, but in most 
cases the disease progressed in other tissues with time. The best outcome 
was in patients with isolated liver manifestation (due to DGUOK mutation) 
where liver transplantation was essentially curative. Most of the liver failures 
in mitochondrial disease patients were due to valproic acid treatment of 
epilepsy, which is toxic for some patients with POLG mutations (68). The 
survival after transplantation was close to national averages, suggesting this 
as one of the treatment options after a careful risk-benefit assessment (113). 
Liver transplantation in Alpers-Huttenlocher disorder is not recommended 
given the fatal neurological course of the disease (117). 
Allogenic haematopoetic stem cell transplantation has been suggested as 
a treatment for MNGIE disorder to restore thymidine kinase enzyme activity in 
blood cells and thereby reduce toxically high levels of thymidine and 
deoxyuridine in blood and other tissues. A retrospective analysis of 24 patients 
showed that if the donor HLA antigen match was 10/10 and transplantation 
age <30, outcome was beneficial. Thymidine kinase activity was restored 
quickly, but clinical improvement took time, even years. (118)  
2.2.4.3 Preventive modalities 
In case of a family being at risk to get a child with a mitochondrial disease, 
preventive modalities can be considered. Prenatal diagnosis from 
amniocentesis or chorionic villus sampling (CVS) is possible. Preimplantation 
genetic diagnosis is used to analyze genetic content of (a) very early stage 
embryo(s). In this, eggs of the mother are collected and fertilized in vitro. From 
a 3-day old embryo (8-cell stage), one of the blastomeres is investigated for 
the presence of known pathogenic mutation. A healthy embryo (or two) is 
implanted to the mother’s uterus (Figure 6A). (119)  
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In case of heteroplasmic mtDNA point mutations, small insertions or 
deletions, using the above mentioned methods is not that straightforward. The 
heteroplasmy of mutated mtDNA in amniotic fluid, CVS and a blastomere is 
shown to be close to that of the whole fetus (33), but caution is warranted as 
unexpected exceptions might exist (120). An embryo, with heteroplasmy 
below a disease-specific threshold level for manifestation is deemed healthy, 
but as the threshold level is difficult to determine and termination of pregnancy 
with heteroplasmy near this level brings ethical concerns. 
Unfortunately, these approaches are not applicable when there is a great 
risk for the fetus to have a high heteroplasmy level of mutated mtDNA (when 
mother has a high heteroplasmy). However, recent advances in technology 
and legislation have enabled a way to overcome this problem: mitochondrial 
replacement therapy. In this technique, the nucleus of the mother’s egg (or 
pronucleus of the embryo) is transferred to a donated egg (or embryo) 
deprived of its nucleus (or pronucleus) (119, 121). The fertilized egg is then 
implanted to the mother’s uterus (Figure 6B). Some maternal mitochondria 
carryover might happen, accounting only for a very low percentage of total 
mitochondrial content of the embryo. The developing fetus has genetic 
material from three individuals, donated mtDNA accounting for only <1% of 
the whole genetic material (119). This therapy was first approved in the UK in 
2015 and has been used with promising results (122). This method brings 
some ethical concerns, discussed elsewhere (123–125). 
 
 
Figure 6.  Simplified illustration of A) preimplantation diagnosis B) mitochondrial replacement 
therapy. Illustration: Kustaa Lehtonen 
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2.3 MOUSE MODELS FOR MITOCHONDRIAL 
DISORDERS 
To study mitochondrial disease mechanisms, and to develop treatment for 
these devastating diseases, several genetically modified mouse models have 
been developed. This approach offers a great means to study disease in a 
controlled environment with homogeneous background. 
An optimal disease model would have the same pathogenic mutation as 
patients and manifest with similar symptoms. This is not always possible, if the 
mouse protein is very different in its amino acid sequence or function. 
Sometimes a homologous mutation causes a different phenotype, as is the 
case in TK2 mice. Similar to humans, these mice show mtDNA depletion and 
OXPHOS deficiency, but in mice, the most severe symptoms were in CNS 
instead of muscle (126). Despite the challenges, the cellular processes still 
resemble each other and studies conducted using animal models often help 
to shed light on the disease pathogenesis as well as to develop treatment 
(127). 
Introducing specific mutations to mtDNA has so far not been technically 
feasible, since introduction of DNA to mitochondria has not been possible 
(128). Disease models with mtDNA mutations have, however, been created 
by fusion of mutated mitochondria from somatic cell to an embryonic stem cell 
(ES cell). The resulting chimeric blastocyst is implanted to a pseudo-pregnant 
female. Developing pups are chimeric to mutant and wild-type mtDNA and 
mating of these females to wild-type males yields heteroplasmic offspring with 
varying phenotype (129, 130). Using a similar technique, Inoue et al (131) 
created Mitomice, a model that carries a heteroplasmic mtDNA deletion in all 
tissues and also transmits it to the offspring. This technique is challenging, 
since in some cases, there seems to be germline selection against the 
deleterious mutation in subsequent generations (130). 
Editing nuclear genes is more straightforward. Genes can be silenced 
completely (called a gene knock out, KO), reflecting the situation in humans 
where a mutation causes for example a premature stop codon and preterm 
termination of protein synthesis, abolishing the function of the protein. Some 
gene deletions cause embryonic lethality (132, 133) and thus conditional 
methods are developed to circumvent such phenotypes by making tissue-
specific KOs (as adipose tissue specific TFAM-KO (134)) or by making an 
inducible KO model (135). 
Alternatively, a genomic construct with a mutation can be directed to the 
endogenous gene locus by homologous recombination, to generate a knock-
in mouse model. Mutator mice have a defective POLG exonuclease activity as 
a critical aspartate residue is replaced with an alanine (136). These mice age 
prematurely due to somatic mtDNA mutations and dysfunction of 
mitochondrial RC. 
The modified gene can also be injected to fertilized egg where it randomly 
integrates to genome. These transgenic mouse models express the mutated 
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gene as well as the wild type gene. This is how Tyynismaa et al created the 
Deletor mouse, a disease model with late-onset mitochondrial myopathy that 
readily replicates features of human PEO disease: accumulation of multiple 
mtDNA deletions and COX-deficient muscle fibers in skeletal muscle (137). 
These mice have a homologous dominant mutation in mitochondrial DNA 
helicase Twnk as Finnish patients with adPEO (138). Further characterization 
of this model revealed an AARE (amino acid response element) regulated 
transcriptional response, including induction of fibroblast growth factor 21 
(Fgf21). FGF21 is a PPAR-α (peroxisome proliferator-activated receptor 
alpha) regulated (139) cytokine normally secreted by the liver (140). It is known 
to regulate glucose uptake in adipose tissue and to lower blood glucose and 
weight in diabetic and obese rodents (140). In Deletors, muscle mRNA 
expression of Fgf21 increased along with COX-negative muscle fibers. 
Induction of expression was not detected in other tissues studied (liver, brain, 
fat), but has later been detected induced in Deletor heart (unpublished data). 







3 AIMS OF THE STUDY 
The aims of this doctoral thesis are: 
 
1) to develop and characterize new serum biomarkers for mitochondrial 
disease 
2) to validate serum biomarkers and study the mechanism for biomarker 
induction 
3) to discover novel genetic causes of mitochondrial disorders utilizing 






4 MATERIALS AND METHODS 
Detailed methods are given in articles I-III. 
4.1 ETHICAL ASPECTS 
These studies were approved by institutional ethics review boards and the 
declaration of Helsinki was followed. Participants (or guardians) gave written 
informed consents. 
Animal procedures were performed according to protocols approved by the 
ethical boards for animal experimentation for each collaborating center. All 
experiments were done in accordance with good practice of handling 
laboratory animals and of genetically modified organisms. 
Study participants were aware of the purposes of the study, magnitude and 
nature of possible discomfort caused and everyone was given a possibility to 
ask further questions about the study. None of this affected the treatment or 
patient car. All participants were given a possibility to quit participation at any 
point without having to name a reason. 
We have minimized sampling harm by drawing a blood sample 
simultaneously with other diagnostic blood tests and doing it during 
anaesthesia when possible. Blood volume drawn at any one time has not 
exceeded 5% of body weight in children less than 10kg in weight. 
4.2 PATIENT MATERIAL 
Study subject inclusion for studies I and II are shown in Figure 7. In 
Suomalainen et al, pediatric control patients (n=18) were collected 
prospectively from Helsinki University Central Hospital as they attended the 
hospital for a non-mitochondrial disorder. In addition, 7 child controls and 49 
adult controls were volunteers. 
Patients with non-mitochondrial disorders or conditions studied in paper II 
were originally recruited for other studies and detailed information of these 
subjects is published elsewhere: ALS (141), cardiomyopathy (142), lymphoma 
(143), metastasized colorectal cancer (mCRC) (144), nonagenarians (145), 
primary biliary cirrhosis (PBC) (146), primary sclerosing cholangitis 
(PSC)(146), statin-induced myopathy (SM) (147). Fibromyalgia patients’ 
samples were collected from pain outpatient clinics in Helsinki University 
Central Hospital, excluding patients with a diagnosed muscle disorder and/or 







Figure 7.  Flowchart of study subject inclusion in studies I (orange) and II (green). Text in bold 
highlights included subjects. Abbreviations: LCHAD, long-chain 3-hydroxyacyl-CoA 
dehydrogenase deficiency; LHON, Leber’s hereditary optic neuropathy; KSS, 
Kearns-Sayre syndrome; MELAS, mitochondrial encephalomyopathy, stroke like 
episodes and lactic acidosis; MERRF, myoclonic epilepsy with ragged-red fibers; 
MIRAS, mitochondrial recessive ataxia syndrome; MLASA, mitochondrial myopathy 
with sideroblastic anemia; MM, mitochondrial myopathy; MNGIE, mitochondrial 




In study III, the index patient (II-2 of family I) was examined and treated in 
Helsinki University Central Hospital and parents gave written informed consent 
for participation in the study. Patients of family II were published originally 
elsewhere (148). 
4.3 ANIMAL MODELS 
Mitochondrial myopathy mouse models were analyzed for their serum FGF21 
concentration and muscle Fgf21 mRNA expression. Deletor mice have a 
homologous dominant mutation to Finnish patients with adPEO (in-frame 
duplication of amino acids 353-365 in Deletor corresponding to duplication of 
amino acids 352-364 in human) (138) in mitochondrial DNA helicase Twnk. 
This strain was generated in our own laboratory (149). K320E-TwinkleMyo mice 
have a muscle-specific Twnk mutation (150). MitoMice carry a single 
heteroplasmic mtDNA deletion in tissues causing combined RC deficiency in 
muscle in high heteroplasmy (131). Ndufs4-KO mouse model causes a severe 
CI deficiency in muscle and brain (151). Mpv17-KO mice have mtDNA 
depletion and COX-negative fibers in muscle (152). Surf1-KO mice have CIV 
assembly defect, which is seen as decreased CIV activity in muscle (153). 
4.4 ANALYSIS OF SERUM BIOMARKERS 
Serum biomarker concentrations in patient serum/plasma were measured (by 
me) blinded for patients’ group allocation with commercially available ELISA 
(FGF21: primarily BioVendor, Brno, Czech Republic; validation of the results 
with an independent ELISA kit from R&D Systems, Minneapolis, MN. GDF15: 
R&D Systems, Minneapolis, MN) according to manufacturers’ instructions. 
Samples were diluted 1:2 (FGF21) and 1:4 (GDF15) unless concentration 
exceeded that of the highest standard. Serial dilution of concentrated samples 
was performed to obtain a more reliable result. All samples were analyzed in 
duplicates. Mouse samples were measured (by S. Forsström) with a 
Quantikine Mouse Fgf21 immunoassay (R&D Systems, Minneapolis, MN). 
Absorbance measurements were performed using a SpectraMax 190 
absorbance microtiter plate reader (Molecular Devices, Sunnyvale, CA). 
4.5 ANALYSIS OF MOUSE QUADRICEPS FEMORIS 
FGF21 EXPRESSION 
After total tissue RNA extraction, qPCR was run and Fgf21 expression 
analyzed as described elsewhere (154) (by S. Forsström). 
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4.6 ANALYSIS OF MTDNA DELETION % IN MITOMICE 
Determination of heteroplasmy level in Mitomice muscle samples was done 
with Southern blot as described elsewhere (155) (by S. Forsström). 
4.7 EXOME ANALYSIS 
Exome analysis was performed for patient II-2 in study III after mtDNA 
sequencing did not reveal any pathogenicity. Patient’s total DNA was enriched 
by NimbleGen Sequence Capture 2.1 M Human Exome v1.0 array followed 
by sequencing with the Illumina Genome Analyzer-IIx platform. Variants were 
called according to variant calling pipeline used in Finnish Institute for 
Molecular Medicine (FIMM). This method revealed 58 685 SNVs with 53.23% 
of targets being covered at a minimum of 20-fold. These variants were then 
prioritized (by me and others) using a filtering strategy for likely disease 
causing variants (see results chapter 5.4.1). 
NGS yields tremendous amount of genetic information that is considered 
classified. All data are stored encrypted and anonymously with only approved 
researchers having access to it. 
4.8 PROTEIN KINETICS ASSAY 
Mutated FARS2 was expressed in Escherichia coli and protein function was 
measured in an enzyme kinetics assay in vitro as described elsewhere (156). 
Substrate binding and catalytic activity was measured for each mutation 
separately. Protein stability was examined by unfolding the protein and, after 
incubation, measuring the percentage of refolded protein with enzyme activity 
assay. These analyses were performed by our US collaborators (S.S. 
Yadavalli, E.M.Caruso  and M. Ibba). 
4.9 STATISTICAL ANALYSES 
The normal cut-off value for serum FGF21 and GDF15 was determined as 95th 
percentile of a healthy control group. In study I, the cut-off limit for FGF21 was 
200pg/ml, whereas in study II, it was 331pg/ml for FGF21 and 1014pg/ml for 
GDF15. 
Patient data are expressed as mean (SD) (study I) or median (IQR) (study 
II). Mouse data variation is expressed as mean (SD). 
Spearman’s rank correlation analysis was used for analysing associations 
of S-FGF21 levels with continuous numeric variables (amount of COX-
negative muscle fibers, body mass index (BMI), other biomarkers (including 
GDF15), age, deletion percentage in muscle of Mitomice, quadriceps femoris 
expression of FGF21). Nonparametric association was considered significant 
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if the r value was greater than 0.5 and p<0.05. In case r exceeded 0.5, linear 
regression was performed, and R2 and P (capital p) value for goodness of fit 
are shown. 
We used the Mann-Whitney U test (study I) or Kruskal–Wallis (human) or 
1-way analysis of variance (ANOVA) (mice) followed by multiple comparisons 
test to compare FGF21 concentrations between patients and controls (study 
II). 
To determine the diagnostic ability of biomarkers, we plotted the receiver 
operating characteristic (ROC) curves and calculated the area under the curve 
(AUC). Chi-square and Fisher’s exact tests were used to calculate 
sensitivities, specificities and predictive values of biomarkers. 
We did all statistical analyses with Stata (version 11.0) and PRISM 5 (study 
I) and PRISM 6 (paper II) (Graph Pad Software, La Jolla, CA). Two-sided p 
values were deemed significant at <0.05. Statistical analyses for study I were 
performed by K. Pietiläinen, for study II by me and S. Forsström and for study 






5.1 FGF21 IS A NOVEL SERUM BIOMARKER FOR 
MUSCLE-MANIFESTING MITOCHONDRIAL 
DISORDERS (I) 
Since FGF21 was found elevated in plasma of a mitochondrial myopathy 
disease model, Deletor (137) (see chapter 2.3), we decided to examine serum 
FGF21 concentrations in patients with mitochondrial myopathy. Samples were 
collected retrospectively from multiple centers to gather a large cohort of these 
rare disorders. We were able to sample 67 patients with an evident 
mitochondrial disease, 34 disease controls and 74 healthy controls. In 
addition, since FGF21 was earlier found to be positively associated with body 
weight (157), we examined five anorexic patients and eight obese individuals 
to control the potential effects of body weight in FGF21 serum levels in our 
patients. 
5.1.1 S-FGF21 IS SPECIFIC TO MITOCHONDRIAL MYOPATHIES 
Analysis of serum/plasma FGF21 concentration revealed significant induction 
of FGF21 in mitochondrial disorders, both in adults (mean 820pg/ml (SD 1151) 
vs healthy controls 76pg/ml (58), p<0.0001)) and children (1983pg/ml (1550) 
vs healthy controls 76pg/ml (58), p<0.0001). FGF21 concentration seemed to 
be higher in patients with mainly muscle phenotype (MELAS) than patients 
with mainly CNS manifestation (MIRAS). For MELAS, MIRAS and MNGIE 
(mitochondrial neurogastrointestinal encephalopathy), disease severity 
seemed to be associated with higher FGF21 value. 
We analyzed a number of non-mitochondrial myopathies and other 
metabolic disorders to study specificity of FGF21 induction. No difference in 
S-FGF21 was detected in these groups, neither in adults nor children, when 
compared to healthy controls. 
Despite the role of FGF21 in starvation (158–160), as well as its previously 
reported associations with BMI (157), patients with anorexia nervosa (BMI 15-
17m2) or obese individuals showed no difference in S-FGF21 compared to 
healthy controls. Association of BMI with S-FGF21 was not significant, neither 
in healthy controls nor in adult mitochondrial disease patients. 
Liver is a known source of circulating FGF21 during starvation (158), and 
thus we asked whether the detected induction in serum could be explained by 
hepatopathy. Due to the retrospective nature of the study, liver function test 
results were not available from all patients, but in those patients that these 
measures were available (23 adults, 13 children), no evidence was found to 
support this possibility. However, muscle tissue samples were available from 
five adult mitochondrial disease patients, and the expression of FGF21 was 
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determined. Similar to results in serum, MELAS patients with a considerable 
number of COX-negative fibers in muscle showed a greater induction in 
FGF21 expression than MIRAS patients, who have mild muscle manifestation 
but prominent brain symptoms. As in Deletor mice, also in patients the number 
of COX-negative fibers correlated with S-FGF21 value, indicating that the sick 
muscle fibers, instead of liver, secrete FGF21 to blood. 
5.2 FGF21 AND GDF15 ARE BOTH INDUCED IN 
MITOCHONDRIAL MYOPATHIES (II) 
After our original study, others have replicated our results (62, 161, 162) as 
well as described another serum biomarker for mitochondrial diseases, 
GDF15 (163, 164). GDF15 is a member of the transforming growth factor beta 
(TGF-β) superfamily (165) and it is known to be secreted by liver, with 
expression being upregulated in liver tissue injury (166). Regarding 
mitochondrial diseases, GDF15 was found induced in a cell model of 
mitochondrial dysfunction, and increased amounts of this protein were then 
also detected in a small cohort of mitochondrial disease patients (MELAS, 
KSS, mitochondrial myopathy and mitochondrial disease) (163). 
 
Table 3.  Accuracy and efficacy of diagnostic biomarkers in detecting mitochondrial myopathy 
from other clinically relevant differential diagnosis (non-mitochondrial myopathy, ALS 
(amyotrophic lateral sclerosis) and healthy control). Combination of FGF21 and GDF15 
(in table rows 3 and 4) are only calculated for patients with both biomarkers measured 
(unpublished data). “FGF21 or GDF15” means that either one or both of the biomarkers 
is induced (vs. both normal) and “FGF21 and GDF15” means both biomarkers are 
induced (vs either one or both normal). *Results for lactate, pyruvate, L/P and CK 
obtained from paper I. Bolding indicates the two best values in each column. Statistics 
were performed with PRISM 7 (Graph Pad Software, LA Jolla, CA) and Fisher’s exact 
test was used with two-sided p-value deemed significant at <0.05. Cut offs were 
331pg/ml and 1014pg/ml for FGF21 and GDF15, respectively. Abbreviations: L/P, 
lactate to pyruvate ratio; CK, creatine kinase. 
 
We performed a meta-analysis of muscle-manifesting patients of our 
previously published data (paper I), two other studies (the only ones available, 





















FGF-21 67.3 57.8-75.8 89.3 83.2-93.7 82.6 73.3-89.7 78.2 71.3-84.2
GDF-15 76.1 64.5-85.4 86.4 77.4-92.8 81.8 70.4-90.2 81.7 72.4-89.0
FGF21 or GDF15 83.1 72.3-91.0 84.1 74.8-91.0 80.8 69.9-89.1 86.1 76.9-92.6
FGF21 and GDF15 56.3 44.1-68.1 97.7 92.0-99.7 95.2 83.8-99.4 73.5 64.6-81.2
Lactate* 63.0 47.6-76.8 92.8 83.9-97.6 85.3 68.9-95.1 79.0 68.5-87.3
Pyruvate* 73.9 51.6-89.8 87.2 74.3-95.2 73.9 51.6-89.8 87.2 74.3-95.2
L/P* 43.5 23.2-65.5 100.0 92.5-100.0 100.0 69.2-100.0 78.3 65.8-87.9
CK* 43.8 26.4-62.3 73.7 62.3-83.1 41.2 24.7-59.3 75.7 64.3-84.9
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genetically verified mitochondrial disease patients and 13 new non-
mitochondrial myopathy (non-MM) patients (see Figure 7 for patient inclusion 
flowchart). We analyzed both biomarkers from our patients whenever possible. 
Both markers were highly induced in patients with mitochondrial myopathy 
(MM) (FGF21 median 578pg/ml (IQR 289-1187) vs 66pg/ml (48-104) of 
controls; GDF15 2146pg/ml (1024-4312) vs 328pg/ml (235-474) of controls) 
and they also correlate to each other (r=0.61, p<0.0001). Sensitivities 
(proportion of true MM patients correctly identified as such) of FGF21 and 
GDF15 to detect a mitochondrial disease with muscle manifestation were 
67.3% (57.8-75.8%) and 76.1% (64.5-85.4%), respectively (Table 3). 
5.2.1 FGF21 AND GDF15 ARE INDUCED THE MOST IN MYOPATHIC 
DISEASES CAUSED BY A MITOCHONDRIAL TRANSLATION 
DEFECT 
To study whether the trigger for biomarker induction is in the RC defect or 
somewhere upstream, we classified mitochondrial myopathy patients into 
three categories based on their genetic defect: 1) defects affecting 
mitochondrial translation (mt translation) 2) primary mtDNA deletions or 
defects leading to multiple mtDNA deletions (mtDNA deletions) 3) defects of 
RC subunits or assembly factors (RC structure & assembly). Moreover, we 
also analyzed quadriceps femoris muscle of mitochondrial myopathy mouse 
models (Deletor (149), K320E-TwinkleMyo (150), MitoMice (131), Surf1-KO 
(153), Ndufs4-KO (151), Mpv17-KO (152)) for Fgf21 mRNA expression and 
drew serum to measure circulating FGF21 concentration. These mice were 
categorized similarly to patients (albeit no translation group). 
In human, both biomarkers were significantly (p<0.0001) elevated in 
translation and deletion groups compared to controls (675pg/ml (437-1504) 
and 347pg/ml (206-1062) vs 66pg/ml (48-104) for FGF21, 3092pg/ml (1844-
4868) and 1520pg/ml (852-3403) vs 328pg/ml (235-474) for GDF15, 
respectively) (Figure 8 and 9). Both of these mutation types eventually lead to 
a translational defect. 
Similarly in mice, defects causing mtDNA deletions caused a significant 
induction in FGF21 in serum (mean 1163pg/ml (SD 625) vs controls 379pg/ml 
(233), p<0.0001) as well as in quadriceps femoris (QF) Fgf21 mRNA 
expression (10.9 times higher relative expression (SD 9.3), p<0.0001). 
5.2.2 MUTATIONS IN RC STRUCTURAL SUBUNITS OR ASSEMBLY 
FACTORS DO NOT CAUSE BIOMARKER INDUCTION 
Unlike in the first two groups described above, defects affecting RC structural 
subunits or assembly factors did not induce these markers to that extent. 
FGF21 was only mildly elevated (335pg/ml (54-604) vs 66pg/ml (48-104), 
p<0.05) while GDF15 showed no difference to controls (512pg/ml (348-1178) 
vs 328pg/ml (235-474), non-significant) (Figure 8). 
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In mice of the same group (Surf1-KO and Ndufs4-KO), serum FGF21 was 
not induced (335pg/ml (SD 96) vs 379pg/ml (SD 233), non-significant) and 
neither was QF Fgf21 expression (0.9 times relative expression (SD 0.5), non-
significant) (Surf1-KO, Ndufs4-KO and Mpv17-KO). 
5.3 FGF21 IS NOT INDUCED IN NON-MITOCHONDRIAL 
DISORDERS (II) 
As multiple differential diagnoses exist, it is important to validate the accuracy 
of these biomarkers to correctly identify MM from non-MM. For this, we 
analyzed 21 patients with a muscular dystrophy, 4 with a congenital myopathy, 
16 with an inflammatory myopathy and 12 with other types of myopathies (17 




Figure 8.  Serum biomarkers FGF21 and GDF15 in non-mitochondrial disorders and 
conditions, mitochondrial myopathies (MM) and controls. Patients with MM (in red) 
are categorized to three groups according to the genetic defect. ALS, amyotrophic 
lateral sclerosis; mCRC, metastasized colorectal cancer; PBC, primary biliary 
cirrhosis; PSC, primary sclerosing cholangitis; SM, statin-induced myopathy in 
acute and post-acute phase; MM, mitochondrial myopathy; RC, mitochondrial 
respiratory chain. Each groups’ median was compared to controls’ median (Dunn’s 
multiple comparisons test) and statistical significance of the difference is indicated 
as asterisks: * p<0.05, **** p<0.0001. Statistics were performed with PRISM 7 
(Graph Pad Software, LA Jolla, CA). Note the discontinuous Y-axis. Parentheses 
indicate number of patients in each group. 
Neither of the serum biomarkers were significantly different in non-MM than in 
controls (101pg/ml (46-309) vs 66pg/ml (48-104) for FGF21, 796pg/ml (344-
1056) vs 328pg/ml (235-474) for GDF15). Among conditions typically 
examined in muscle clinics, specificities (proportion of non-MM patients 
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correctly identified as such) of these tests were 89.3% (83.2-93.7%) for FGF21 
and 86.4% (77.4-92.8%) for GDF15 (Table 3). 
Both biomarkers have also been studied widely in non-mitochondrial 
disorders. FGF21 has been associated with coronary heart disease (167), fatty 
liver (168, 169), type 2 diabetes (168, 170) and metabolic syndrome (170). 
Induction of GDF15 has been reported in for example ovarian cancer (171), 
chronic obstructive pulmonary disease (COPD) (172) and impaired fasting 
glucose (173). 
We wanted to assess biomarker concentrations in non-mitochondrial 
diseases or disease traits that resemble mitochondrial diseases in some 
aspects. We chose patients/subjects with muscle involvement (ALS, 
cardiomyopathy, fibromyalgia, nonagenarians, SM), liver involvement (PBC, 
PSC and mCRC) or with a severe multi-organ disease (lymphoma, mCRC) to 
compare their biomarker levels to controls. 
It turned out that besides mitochondrial myopathy, mCRC is the only group 
differing from controls in FGF21 concentrations (170pg/ml (75-566) vs 66pg/ml 
(48-104), p<0.05). However, GDF15 was induced in a wide variety of 
conditions, including cardiomyopathy (558 pg/mL (456–993), p<0.05)), mCRC 
(2,082pg/mL (1,332–2,625), p<0.0001), nonagenarians (2,007pg/mL (1,397–
3,489), p<0.0001), PBC (3,706pg/mL (2,706–6,794), p<0.0001) and PSC 
(2,026pg/mL (774–4,371), p<0.0001) when compared to controls (328pg/mL 
(235–474)) (Figure 8). 
5.3.1 PRIMARY MITOCHONDRIAL DEFECTS IN MUSCLE ARE 
ASSOCIATED WITH FGF21 INDUCTION 
In line with the original findings (137, 174), results of paper II support FGF21 
secretion by the muscle. In mice, serum FGF21 values associated with mtDNA 
deletion% in MitoMice (5)R2=0.48, p<0.05) and QF Fgf21 mRNA expression 
levels in mice with mitochondrial myopathy (R2=0.43, p<0.001). 
Interestingly, it seems that the induction requires a primary mitochondrial 
defect affecting mitochondrial translation or having mtDNA deletions. First, 
patients with a statin-induced myopathy showed no induction in S-FGF21 
despite the CoQ10 lowering effect the drug has (175). Second, ALS is 
associated with secondary mitochondrial dysfunction (176), with no induction 
of S-FGF21. Third, according to the literature, nonagenarians (people >90 
years of age) are shown to accumulate mtDNA deletions in tissues and a 
reduction of COX activity in muscle (111), still not showing induction in S-
FGF21. Fourth, patients with inclusion body myositis (IBM), with considerable 
amounts of COX-negative fibers in muscle, had normal or almost normal S-






Figure 9.  Simplified illustration of mitochondrion showing levels of serum FGF21/GDF15 
according to genetic aetiology in patients with mitochondrial myopathy. Asterisk 
indicates median biomarker value (shown, if number of patient with this gene 
mutation is more than three). Bolding indicates values above normal range 
(331pg/ml for FGF21 and 1014pg/ml for GDF15). YARS2 protein catalyzes the 
attachment of tyrosyl to its tRNA. Abbreviations: ΔmtDNA, single large scale mtDNA 
deletion; mRNA, messenger RNA; tRNA, transfer RNA; rRNA, ribosomal RNA; CI-
CV are OXPHOS complexes I to V. tRNA-category includes mutations in all tRNAs. 
HGNC approved gene symbols are used. X=not measured. Illustration: Kustaa 
Lehtonen 
5.4 DEFECT IN FARS2 IS A NOVEL GENETIC CAUSE 
UNDERLYING FATAL INFANTILE ALPERS 
ENCEPHALOPATHY (III) 
At the initiation of this study, the genetic diagnosis of disorders had been 
undergoing a revolutionary increase in efficiency. Instead of single genes, we 
could now use massively parallel high throughput sequencing to analyze all 
protein-coding regions of the genome in a patient, by whole exome 
sequencing (WES). We decided to utilize this chance and used WES to search 
for a causative gene defect in a patient with fatal infantile Alpers 
encephalopathy. 
Our index patient’s disease started at the age of two days with treatment 
resistant myoclonic jerks. Blood and CSF lactate were elevated, suggestive of 
mitochondrial disease, while mtDNA sequence was normal. Plasma alanine, 
isoleucine and leucine were increased and she had generalized 
aminoaciduria. Histochemical activity of muscle COX was weak and 
 
48 
accumulation of lipids and glycogen were detected in muscle tissue. RC 
function was reduced: NADH: cytochrome c oxidoreductase activity was 114% 
of controls’ mean, succinate: cytochrome c oxidoreductase 21%, succinate 
dehydrogenase 50% and COX 16% of controls’ mean. Liver biopsy sample 
showed accumulation of glycogen, lysosomal iron and copper in addition to 
enlarged hepatocytes. Disease progressed rapidly, observed as generalized 
extensive brain atrophy in MRI at the age of 3 months. Brain MRS at three 
months showed elevated lactate as well as decreased NAA content supporting 
the diagnosis of a mitochondrial disease.  The patient’s myoclonic jerks 
continued and she had no psychomotor development. She died at the age of 
8 months. Autopsy revealed severe cerebral atrophy, brain weighting only 
30% of an age matched control. This patient was the second child of the family, 
the sister having died of a similar disease before the age of two. 
5.4.1 EXOME SEQUENCING REVEALS PUTATIVELY PATHOGENIC 
VARIANTS IN FARS2 
Exome sequencing of the patient DNA sample yielded 58 685 SNVs that were 
filtered according to the following criteria: The putatively pathogenic variant 
should be 1) in a protein-coding region of a gene 2) homozygous or compound 
heterozygous 3) predicted pathogenic by SIFT Genome tool 4) localized to 
mitochondria (according to MitoCarta 1.0 (31) 5) segregating with phenotype 
in the family 6) not present in population controls (400 Finnish control 
chromosomes and the 1000 Genomes database). 
Identified variants in mitochondrial phenylalanyl-tRNA synthetase 
(mtPheRS, encoded by FARS2) were the only ones passing through this filter 
system. This protein catalyzes attachment of amino acid phenylalanine to its 
cognate tRNAPhe in mitochondria and is thus involved in mitochondrial 
translation, fitting nicely as a cause of the combined RC enzyme deficiency 
detected in index patient.  
These variants were in exons 5 (c.986T>C, p.I329T) and 6 (c.1172A>T, p. 
D391V) (RefSeq NM_006567.3) of the FARS2 gene and were conserved 
down to plants (Arabidopsis thaliana). We sequenced the protein-coding 
exons and exon-intron boundaries of FARS2 in 82 patients with mitochondrial 
encephalopathy by Sanger sequencing but found no other patients with likely 
pathogenic mutations in this gene. The pathogenicity was strongly supported 
by another family with FARS2 mutation (c.432A>G, p.Y144C), published 
elsewhere as a variant of unknown significance (VUS) (148). We combined 
our knowledge in the two research groups and did functional and structural 
validation of pathogenicity with the mutated proteins. 
5.4.2 DETECTED VARIANTS DISRUPT PROTEIN FUNCTION 
To model the mutated amino acids the crystal structure of mtPheRS protein 
was utilized, which revealed the motifs in which these amino acids are located 
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and allowed predictions of the functional consequences of the mutations to be 
made. First, p.I329T was predicted to widen the ATP binding pocket of the 
protein, decreasing the affinity of the enzyme to ATP. Second, both p.D391V 
and p.Y144C were predicted to affect the functional rotation mechanism of the 
protein that is needed upon substrate binding. 
Our collaborators in USA (SS. Yadavalli and M. Ibba) expressed the wild 
type (Figure 10A) and mutated proteins in E. coli to study the effects of these 
mutations on protein function. They were able to show that p.I329T indeed 
decreases the ATP dependent amino acid activation efficacy of the protein 
(Figure 10B). The mutation p.D391V was found to have an increased Km for 
phenylalanine, which may decrease mtPheRS aminoacylation activity (Figure 
10C), whereas p.Y144C compromises the binding of tRNAPhe to mtPheRS 
hampering efficient enzyme function (Figure 10D). 
In addition, capacity of refolding and thus reactivation of p.I329T and 
p.D391V single mutant proteins were disrupted compared to wild type protein, 
implicating a decrease in stability of the protein. 
In concordance with these observations, decreased amounts of RC 
complexes were detected by BN-PAGE (blue native polyacrylamide gel 
electrophoresis) in brain and muscle of our index patient implying decreased 
translation of these proteins. CIV was reduced in both, and CI deficiency was 




Figure 10.  Schematic representation of mutated mtPheRS proteins. A) wild type mtPheRS 
showing normal localization of tRNAPhe (red), phenylalanine (green triangle) and 
ATP (yellow stick) B) mtPheRS with p.I329T mutation, with decreased capability to 
bind ATP in order to activate phenylalanine C) p.D391V mutation reduces the 
capacity of mtPheRS to bind to phenylalanine. D) p. Y144C mutant mtPheRS 





We have discovered and studied a novel serum biomarker for muscle-
manifesting mitochondrial disorders. It is the first new serum marker for these 
disorders since the measurements of lactate, pyruvate, their ratio and CK (all 
being in use already before 1980’s (177–180)). In addition, we have studied 
another new serum biomarker, GDF15, and detected similarities as well as 
differences in the induction of these two biomarkers. 
After our original report, induction of FGF21 in mitochondrial myopathies 
has been reported in several studies (62, 164, 181–183) and correlation with 
the amount of COX-negative fibers has been verified (181, 183), supporting 
our data that FGF21 is secreted by the muscle instead of liver or adipose 
tissue as in normal physiology . In all these studies, S-FGF21 exceeds the 
performance of the conventional biomarkers (lactate, pyruvate, their ratio, CK), 
strongly supporting the usage of this biomarker as a diagnostic tool. 
GDF15 seems to be an even more accurate biomarker for mitochondrial 
disorders, demonstrated by an increased AUC in ROC analyses (paper II and 
two publications (164, 181)). Both GDF15 and FGF21 are similarly increased 
in mitochondrial translation defects (paper II) but not in defects directly 
affecting RC complex subunit or its assembly, thereby limiting their usage to a 
subset of RC disorders. However, we show (paper II) that unlike FGF21, 
GDF15 is also induced in many non-mitochondrial disorders and conditions, 
implying that this biomarker is less specific. FGF21 induction seems to require 
a primary mitochondrial disorder, which is not the case with GDF15. First, we 
show in paper II how GDF15 is induced in many non-mitochondrial diseases 
and conditions. Second, although GDF15 levels do not differ in controls and 
non-mitochondrial myopathies as groups (paper II and two publications (181, 
182)), Ji X et al report occasional elevation of GDF15 in those non-
mitochondrial myopathies that show secondary mitochondrial dysfunction 
(181). This is of particular interest, if this kind of difference could be used to 
direct further diagnostics and predict genetic aetiology.  
Association of GDF15 with mitochondrial disease was first reported by 
Fujita et al in cell cybrids containing MELAS mutations, where GDF15 was 
induced in lactate-containing media (163). Before this, they had studied the 
same cells in normal medium (containing uridine) and reported an induction of 
ATF4 (activating transcription factor 4)(184), which is then shown to regulate 
both FGF21 (137) and GDF15 (185). Similar regulation of these biomarkers is 
possibly reflected in mitochondrial disease patients as significant correlation 
between these two biomarkers (164, 181, 182). Furthermore, they are both 
shown to reduce blood glucose levels in diabetic or obese mice (186, 187). In 
concordance, Nikkanen et al detected increased glucose uptake in skeletal 
muscle and heart of Deletors (the mouse model where induction of FGF21 
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was originally found), being a part of the stress response in mitochondrial 
myopathy (154). 
These data indicate that FGF21 and GDF15 have similarities in their 
responses to mitochondrial dysfunction, but also differences, which is 
important information considering mitochondrial disease physiology. Detected 
differences in biomarker induction make it feasible to use them in combination: 
one is sensitive (GDF15), one is specific (FGF21). The usage of biomarkers 
in combination is supported by the higher sensitivity, specificity, positive and 
negative predictive values as compared to the use of biomarkers alone (Table 
3, unpublished data). Presumably, even higher sensitivity could be achieved 
by measuring biomarkers repeatedly at different stages of disease course. 
Accuracies of other diagnostic modalities are quite modest. Lactate and 
pyruvate are susceptible to false results due to a struggling child, postprandial 
sampling or poor sample handling (4). The sensitivity of lactate to detect 
mitochondrial disorders is quite unremarkable (63.0% (CI 47.6-76.8) in paper 
I) as also shown in Debray et al, where 52% of mitochondrial disease patients 
showed occasionally normal lactate values (83). Of tissue samples, skin 
fibroblasts are easiest to obtain, but they often lack the pathology seen in deep 
tissues (188). Among children, muscle biopsy sample is often normal, and 
negative findings do not rule out a mitochondrial disease (189). 
In paper III, we detected FARS2 mutations in infantile onset Alpers-
Huttenlocher disease, adding a new gene to the list of three causative genes 
known at that time. The index patient had intractable myoclonic jerks, signs of 
hepatic disease and no psychomotor development fulfilling the diagnostic triad 
of Alpers-Huttenlocher syndrome. In addition, this patient had decreased NAA 
and elevated lactate in MRS, increased blood and CSF lactate, abnormal EEG 
and a compound defect in RC enzymes. Autopsy revealed neuronal loss, 
spongiosis and gliosis. All of these findings are typical for Alpers-Huttenlocher 
syndrome. This disease was severe, leading to death before the age of two in 
all four patients. 
Detection of novel disease genes/variants needs further validation before 
establishing them as pathogenic. Variants detected in NGS need to be verified 
by Sanger sequencing (or other independent method), since NGS does make 
errors in areas of low coverage. Segregation of disease genotype with the 
phenotype is important to verify. Online databases contain a huge amount of 
important data for first-line validation. Conservation of the amino acid across 
species and variants’ absence (or with recessive diseases, carrier frequency 
<1%)(190) in control populations is supportive of pathogenicity. It is worth 
noting that the control population should be carefully chosen since founder 
effects or haplotypes can interfere with interpretation. This was the case in 
patients with mutated SARS2 (Table 4), where detected variants were absent 
in 212 Palestinian control chromosomes while in the particular village of 
patient’s, carrier frequency was 1:15 (191). 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































example E. Coli or yeast) or advanced computation. Protein crystal structure 
is needed to computationally predict the effect the mutation has to the protein. 
As not all crystal structures are resolved or homology to another species’ 
protein is too little, this prediction is not always possible. 
If the mutation causes a premature stop codon or an alternative splice 
site, the size and possibly also quantity of mRNA or protein should change 
(non-sense mediated decay, splicing, instability of protein) (192–196). The 
mutation can change a targeting sequence, causing mislocation of protein 
(197). 
In silico molecular prediction of the structural changes and the 
functional consequences they have, help to plan further studies. The protein 
can be unstable (as mtPheRS was) or it can have a reduced activity (as 
mtPheRS had) in vitro or in vivo. Once a measurable phenotype is detected, 
a rescue by complementation assay is possible (192, 198, 199). 
mtPheRS dysfunction could have been seen as a reduced mitochondrial 
translation rate or reduced OXPHOS activity (not CII since it is fully nuclear 
encoded). Activity of CI and CIV were reduced in muscle but lack of this 
phenotype in fibroblasts hampered their usage in functional validation. This is 
typical for defects in mitochondrial aaRSs that cause a wide spectrum of 
phenotypes. Disease causing mutations (all recessive) have now been 
detected in all 19 of them (versus only 8 in 2012), 11 of them found using NGS 
methods. Disease phenotype and type of functional validation used in the 
original reports of mutated aaRSs is shown in Table 4.  
American College of Medical Genetics and Genomics (ACMG) has given 
guidelines on how to interpret pathogenicity of a VUS (200). According to these 
guidelines, finding three patients from two families with similar phenotype, the 
absence of detected mutations in the control population, the segregation of 
genotype with phenotype, and the results of the functional analysis of the 
mutated protein together highly indicate that FARS2 is the pathogenic gene. 
This was a fourth gene reported to cause Alpers disease, currently also linked 
to mutations in PARS2 and NARS2 (201). 
The tissue specificity of these disorders is interesting since they all catalyze 
the attachment of an amino acid to its cognate tRNA in mitochondrial protein 
synthesis. Translation impairment per se cannot explain this phenotypic 
variation, but the effect of defective incorporation of specific amino acids to the 
synthetized protein or other (unknown) functions of these enzymes could 
explain the difference. It is possible that the genome contains protective or 
harmful variations elsewhere, modifying the phenotype. 
The success rate of WES to detect a pathogenic mutation in patients with 
an biochemical OXPHOS defect is superior (43-60%) (202) compared to the 
pre-NGS time (16,4%)(203). The best success rate is seen in with no previous 
genetic studies done (which permits the detection of mtDNA mutations also). 
There are multiple reasons for why not all genetic defects are found. The 
mutation can lie outside the targeted area (in introns or in genes not targeted), 
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the disease can be polygenic, the model of inheritance could be different than 
expected (de novo dominant instead of recessive) or the quality of sequence 
analyzed in that region can be poor. Detection of deletions and insertion 
requires additional computation, as these sequence reads do not align with 
reference sequence automatically. Low or no coverage in an area indicates 
possible deletion and this should be further assessed. 
The inheritance model is assumed as recessive, if both parents are healthy. 
However, when studying single patient samples, it is possible that the mutation 
is de novo dominant. In our index patients, WES revealed 841 previously 
unknown variants in a coding region. 22 of them were homozygous and 131 
were compound heterozygous. The remaining 688 were potential dominant 
mutations. Analysis of parental samples would greatly reduce the number of 
these variants, but since approximately 75 de novo mutations occur during 




Figure 11.  Number of novel primary OXPHOS disease genes detected each year (genes listed 
in Table 2). Green indicates nuclear genes detected with next generation 
sequencing (NGS) methods, gray indicates genes found using conventional 
methods. Graph drawn with PRISM 7 (Graph Pad Software, La Jolla, CA). 
NGS brings some ethical concerns as the data could reveal something that 
was not looked for: genetic predisposition to cancer or a genotype of a later 
onset (possibly non-treatable) disease. In our studies, the NGS data filters are 
created to best serve our goal, finding a diagnosis for a mitochondrial disorder, 
leaving other types of variants unobserved. Genetic testing of pedigrees could 
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reveal the true (hidden) biological relationship of family members, knowledge 
that should not be transmitted to the family without their will. In 2013 (an 
update was published in 2015), ACMG created a list of genes whose 
pathogenic mutations should be returned to the clinician treating the patient 
(205, 206). A recommendation of the contents of the informed consent 
obtained from the patient before NGS was developed in 2013 by ACMG (207). 
The usage and development of NGS technology during the last decade 
has enabled searching of the genetic aetiology also in single patients. The 
importance of NGS is also highlighted in Leigh disease, where nearly 30 out 
of 75 disease genes have been reported within the past 5 years (101). NGS 
techniques have enabled the sustained finding of novel genes causing primary 
OXPHOS disorders (Figure 11). Rapid expansion of the genetic library 
warrants re-analysis of NGS data yearly, as variants considered as VUS 




7 CONCLUSIONS AND FUTURE 
PROSPECTS 
Heterogeneity of clinical manifestation of mitochondrial disorders in 
combination with an increasing number of possible genetic aetiology offer a 
complex task for clinicians, which is not simplified by inaccurate diagnostic 
tests available to date. Currently, diagnosis of a mitochondrial disorder relies 
on phenotype, histological evaluation of tissue sample, biochemical OXPHOS 
deficiency and a solid diagnosis is only received with genetic testing. 
Finding a treatment for patients is the ultimate goal of our research. Before 
this, one must find a diagnosis, then to unravel the disease mechanism and 
only then that enables the search of tailored treatment development. Falling ill 
to a disease without a cure is a huge burden to the patient and family and 
uncertainties regarding disease only prolong the discomfort. Diagnosis brings 
clarity to situation and futile assessments can be avoided. Genetic diagnosis 
enables genetic counselling, which, in case of paediatric patients, is especially 
important if parents wish to have more children. 
In the first publication (174), we characterized a novel serum biomarker for 
mitochondrial diseases, after decades of which there were no new biomarkers 
found. We show that it is most likely secreted by the diseased muscle fibers in 
mitochondrial myopathies, reflecting the disease stage in the muscle. The 
trigger for biomarker induction seems to be upstream of RC deficiency, most 
likely in mitochondrial translation. This marker is very specific for primary 
mitochondrial disorders. 
In the second paper (208), we characterized and studied the mechanism 
of another new serum biomarker, GDF15. Similarly to S-FGF21, primary RC 
subunit defect or an assembly factor dysfunction causes a minor induction as 
compared to translational defects and mtDNA deletions. However, this 
biomarker is also induced in a variety on non-mitochondrial disorders, 
although not in the important differential diagnosis such as non-mitochondrial 
myopathies. 
In the third paper (209) we used whole exome-sequencing to identify a 
novel disease gene, FARS2, causing severe infantile onset Alpers-
Huttenlocher hepatoencephalopathy, a disorder previously only linked to 
POLG, TWNK (74) and MTCO2 (75) mutations. Mutated FARS2 hampers the 
function of its product, a mitochondrial phenylalanyl-tRNA synthetase (mt-
PheRS), resulting in a mitochondrial translation defect. Mitochondrial 
aminoacyl-tRNA synthetases are a new group of genes underlying a wide 
variety of disorders, almost all of which have been first described within the 
last decade (Table 4). 
Finding (and reporting) a novel disease gene, mutation or phenotype 
makes the finding of a second patient much more straightforward. Verifying 
the pathogenicity of a mutation in a tissue sample is sufficient to be done once, 
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and further patients do not need to donate any tissue for diagnosis validation 
(other than blood for the genetic testing). 
Although FGF21 and GDF15 are the most accurate biomarkers for 
mitochondrial myopathies currently (Table 3), it is not yet known whether low 
biomarker values indicate normal/unspecific histology and RC enzyme 
activities in muscle suggesting that a muscle biopsy is not needed. To study 
this, we’ve started a multi-center collaboration with a prospective study set 
including all patients providing a muscle biopsy. In addition, it remains to be 
studied whether these biomarkers could benefit diagnosis of mitochondrial 
encephalopathies or if they could help to determine whether variants found 
with NGS are pathogenic. 
During my thesis research, NGS methods have become more readily 
available while prices have sunk. Currently, whole genome sequencing (3.3 
Gbp) is essentially as expensive as whole exome sequencing (30 Mbp) was 
at the time of publication of my third article (2012). Supposedly, the course will 
remain similar making it possible that NGS would be cost-effective as a first 
line diagnostic test within the next decade(s). Increasing knowledge of 
disease-related genes, and frequencies of variants found in healthy people, 
makes the detection of mutations feasible. Possibly, within the next decade, 





Figure 12.  Suggestion for an updated diagnostic flowchart. Serum FGF21 and GDF15 should 
be included as first line diagnostic tests. Positive predictive value for the 
combination of these biomarkers is so high that rapid progression to gene 
sequencing is advised. NGS techniques should replace the traditional sequencing 
methods if a defective gene cannot readily be predicted based on phenotype. 
Abbreviations: L, lactate; P, pyruvate; CSF, cerebrospinal fluid; MRI, magnetic 
resonance imaging; MRS, magnetic resonancy spectoscopy; NAA, N-acetyl L—
aspartate; EMG, electropmyography; EEG, electroencephalography; ECG, 
electrocardiogram; OXPHOS, oxidative phosphorylation; mtDNA, mitochondrial 
DNA; NGS, next generation sequencing. Figure modified from Gorman et al 2016 
and Haas et al 2008.  
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Recently, Nikkanen et al analyzed over 100 metabolites in patients with 
mitochondrial myopathy and IOSCA (infantile onset spinocerebellar ataxia) 
due to TWNK mutation and reported genotype-specific metabolite fingerprints 
(154). Future research will show whether this type of metabolic profiling has 
the potential to become the next generation biochemical analyses for 
mitochondrial disease diagnosis. 
In conclusion, we suggest that serum FGF21 and GDF15 should be used 
as front line diagnostic tests when a mitochondrial myopathy is being 
suspected before proceeding to muscle biopsy. Costs (blood sample draw, 
ELISA analysis) and harm of these analyses are minor compared to the 
benefits, supporting the incorporation of these biomarkers to the spectrum of 
obtainable tests in tertiary care diagnostic laboratories. Despite them not 
detecting mitochondrial RC subunit and assembly factor defects, their positive 
predictive power in combination leaves almost no doubt of the genetic 
aetiology. Low biomarker values do not out rule a mitochondrial disorder and 
thus expert clinical interpretation is needed. We advise to rapidly proceed to 
massively parallel NGS instead of sequencing candidate genes one by one 
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